Alteogen said negotiations for additional global licensing-out deals with multinational pharmaceutical companies are approaching completion, as the company looks to accelerate global partnerships based on its patent strength and commercialization track record.
CEO Tae-Yeon Jeon made the remarks while speaking with reporters on the sidelines of the BIO International Convention 2026 (BIO 2026), held at the San Diego Convention Center in California.
“Some projects are nearing final stages, but timelines vary depending on deal structure and terms across companies,” Jeon said. “We are focusing on maximizing the company’s value while also building partnership structures that support long-term collaboration.”
He added that global pharmaceutical companies have already evaluated the applicability of Alteogen’s ALT-B4 platform across multiple drug modalities, with generally positive feedback.
“If these agreements are finalized, they could represent a different type of technology transfer compared to previous deals,” he said.
Jeon emphasized that global pharma companies assess platform technologies not only on patents but also on CMC (chemistry, manufacturing and controls) capabilities and regulatory execution. He noted that Alteogen’s experience in preparing its first commercial products has significantly strengthened its regulatory documentation and compliance capabilities.
On intellectual property, Jeon expressed confidence in the company’s patent position.
“In the past, due diligence processes involved extensive patent-related questioning,” he said. “Recently, however, much of that scrutiny has already been addressed by partners reviewing prior dispute outcomes, making the process significantly smoother.”
Alteogen noted that no third party has filed invalidation challenges against its core patents, and that certain patent-related proceedings initiated in the United States by competitor Halozyme have been dismissed, which the company says has strengthened market confidence in its technology.
The company is also expanding the application of its platform technology into antibody-drug conjugates (ADCs), bispecific antibodies, and RNA-based therapeutics.
“We are seeing opportunities to move even further ahead in next-generation modalities such as ADCs, RNA therapies, and bispecific antibodies,” Jeon said. “We will continue building toward becoming a global biopharmaceutical company beyond a platform developer.”
Regarding a potential move from KOSDAQ to KOSPI, Jeon said the company is re-evaluating its options.
“Given changes in the market environment compared to last year, we are reassessing the practical benefits,” he said. “We will make a decision soon after considering broader factors such as KOSDAQ revitalization policies and potential new index developments.”
Addressing emerging biotech companies aspiring to follow Alteogen’s path, Jeon stressed that success requires more than technology alone.
“Success in biotech requires not only technology, but also patents, clinical development, regulatory expertise, and business development capabilities working together,” he said. “It is important to build an ecosystem where small biotech firms can grow.”
